alogliptin (Nesina)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

tablet

Adverse effects

Mechanism of action

More general terms

Component of

References

  1. 1.0 1.1 FDA News Release: Jan. 25, 2013 FDA approves three new drug treatments for type 2 diabetes http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm
  2. 2.0 2.1 2.2 White WB et al. for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013 Sep 2 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23992602 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1305889
  3. 3.0 3.1 Zannad F et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet 2015 Mar 9; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25765696 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2962225-X/abstract
    Standl E and Schnell O. DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet 2015 Mar 9 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25765695 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2960037-X/abstract
  4. 4.0 4.1 FDA Safety Alert. April 5, 2015 Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication - Risk of Heart Failure. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm

Database